MARKET

CRTX

CRTX

Cortexyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.27
+0.99
+2.05%
Opening 13:19 10/22 EDT
OPEN
48.61
PREV CLOSE
48.28
HIGH
49.40
LOW
47.40
VOLUME
19.90K
TURNOVER
--
52 WEEK HIGH
73.84
52 WEEK LOW
20.14
MARKET CAP
1.45B
P/E (TTM)
-24.7513
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced that its work will be the subject of abstracts at two upcoming scientific conferences: the 13th Clinical Trials on Alzheimer's Disease Digital Event (CTAD 2020; November 4-7) and the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC; November 9-14).
Business Wire · 3d ago
Anavex 2-73 And GV-971: Turning The Tide Against Alzheimer's Disease
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease.To treat Alzheimer's disease, it is probably necessary to slow down the production of oxidants, remove those oxidants, and repair part of the damage that they cause to the brain.Anavex 2-73 and GV-971 are two drugs that do all three.Some investment in Anavex 2-73 is worth considering at this point in time.
Seekingalpha · 10/07 10:54
Cortexyme Announces GAIN Trial Of Atuzaginstat In Alzheimer's Disease Has Exceeded Study Enrollment Target Of 570 Patients
- Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (NASDAQ:CRTX) today announced that its GAIN Trial for Alzheimer's disease (AD) has exceeded its enrollment target
Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (NASDAQ:CRTX) today announced that its GAIN Trial for Alzheimer's disease (AD) has exceeded its enrollment target · 09/24 12:09
Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the H.C. Wainwright 22nd Annual Global
Business Wire · 09/09 12:00
Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,730,826 relating to Cortexyme’s lead small
Business Wire · 08/27 13:00
Cortexyme Announces Issuance Of Composition Of Matter Patent For Atuzaginstat By The US Patent And Trademark Office
- New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term
New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term · 08/27 12:12
Company News for Aug 18, 2020
Zacks · 08/18 13:21
Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the second quarter 2020 and provided an update on its business.
Business Wire · 08/17 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRTX. Analyze the recent business situations of Cortexyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRTX stock price target is 78.86 with a high estimate of 179.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 91
Institutional Holdings: 15.26M
% Owned: 51.74%
Shares Outstanding: 29.49M
TypeInstitutionsShares
Increased
43
3.88M
New
27
146.44K
Decreased
11
32.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+0.15%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Casey Lynch
Co-Founder/Chief Scientific Officer/Director
Steve Dominy
Co-Founder/Chief Scientific Officer/Director
Stephen Dominy
Chief Financial Officer/Treasurer
Christopher Lowe
Executive Vice President
Leslie Holsinger
Chief Administrative Officer/Secretary
Caryn McDowell
Other
Michael Detke
Lead Director/Independent Director
Una Ryan
Independent Director
Margi Mcloughlin
Independent Director
David Lamond
Independent Director
Margaret Mcloughlin
Independent Director
Christopher Senner
Independent Director
Kevin Young
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRTX
Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cortexyme Inc stock information, including NASDAQ:CRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRTX stock methods without spending real money on the virtual paper trading platform.